TY - JOUR
T1 - Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV
AU - Penzak, S. R.
AU - Chuck, S. K.
AU - Stajich, G. V.
PY - 2000
Y1 - 2000
N2 - Study Objective. To assess the efficacy and safety of HMG-CoA reductase inhibitors (statins) in patients with human immunodeficiency virus (HIV) infection and hyperlipidemia. Design. Retrospective analysis. Setting. HIV clinic. Patients. Twenty-six HIV-infected patients with hyperlipidemia. Intervention. Five patients received pravastatin, 13 lovastatin, 10 simvastatin, and 2 atorvastatin (total 30 courses). Measurements and Main Results. Reductions in cholesterol and triglycerides were used to assess efficacy; creatine kinase (CK), liver enzymes, and myalgia were markers of statin toxicity. After a median of 8.2 and 7.2 months of treatment, the agents collectively reduced median baseline total cholesterol 27% (354 to 263 mg/dl) and triglycerides 15% (513 to 438 mg/dl), respectively. Two patients, one with marked CK elevations, experienced myalgias with lovastatin, and two experienced transaminase elevations 3 or more times the upper limit of normal. Conclusion. Statins are effective in reducing total cholesterol and triglycerides in HIV-infected patients, although lipid levels infrequently return to normal. Lovastatin should be avoided in patients receiving concomitant drugs that may potentiate skeletal muscle toxicity with this agent.
AB - Study Objective. To assess the efficacy and safety of HMG-CoA reductase inhibitors (statins) in patients with human immunodeficiency virus (HIV) infection and hyperlipidemia. Design. Retrospective analysis. Setting. HIV clinic. Patients. Twenty-six HIV-infected patients with hyperlipidemia. Intervention. Five patients received pravastatin, 13 lovastatin, 10 simvastatin, and 2 atorvastatin (total 30 courses). Measurements and Main Results. Reductions in cholesterol and triglycerides were used to assess efficacy; creatine kinase (CK), liver enzymes, and myalgia were markers of statin toxicity. After a median of 8.2 and 7.2 months of treatment, the agents collectively reduced median baseline total cholesterol 27% (354 to 263 mg/dl) and triglycerides 15% (513 to 438 mg/dl), respectively. Two patients, one with marked CK elevations, experienced myalgias with lovastatin, and two experienced transaminase elevations 3 or more times the upper limit of normal. Conclusion. Statins are effective in reducing total cholesterol and triglycerides in HIV-infected patients, although lipid levels infrequently return to normal. Lovastatin should be avoided in patients receiving concomitant drugs that may potentiate skeletal muscle toxicity with this agent.
UR - http://www.scopus.com/inward/record.url?scp=0033813398&partnerID=8YFLogxK
U2 - 10.1592/phco.20.13.1066.35033
DO - 10.1592/phco.20.13.1066.35033
M3 - Article
C2 - 10999499
AN - SCOPUS:0033813398
VL - 20
SP - 1066
EP - 1071
JO - Pharmacotherapy
JF - Pharmacotherapy
SN - 0277-0008
IS - 9 I
ER -